Atomoxetine  Tablets

18, 25, 40, 60, 80 & 100 mg

central nervous system


Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and children over the age of 6.
Unipharm’s Atomoxetine Tablets are all scored, enabling a wider range of dosing for ADHD treatment in comparison with Strattera Capsules, making this a value-added generic product.
Unipharm’s generic Atomoxetine Tablets have been manufactured and marketed in Israel since 2018. This Added Value Product’s Dossier includes a new EU bioequivalence study compared to the EU Reference Listed Drug, Strattera.

  • ATC4: N06BA
  • Strengths: 18, 25, 40, 60, 80 & 100 mg
  • Dosage forms: Tablets & Oral Solution 4 mg/ml (100 ml)
  • EU Dossier is available for submission
  • Out-licensing is offered for all international markets*
  • Zone IVb stability data is available
* Product availability is subject to patent restrictions in countries where applicable patents are in effect

related products